FOLH1 and prostate carcinoma: This review examines the current evidence on imaging biomarkers and complementary diagnostic techniques used for patient selection, treatment monitoring, and response assessment in [177Lu]Lu-PSMA-617 therapy for metastatic castrate resistant prostate cancer.